Metraipolis › archive › dc_37bfde9b74fb
Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL — Europe PMC PMID:41267399
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41267399
- DOI
- 10.1016/j.ymthe.2025.11.026
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-08T11:00:57.373Z
- SHA-256 of the archived text
773c6f1a1998baaa9c5f95f9804e752c16706bb03608b2809074b926ead2495b- Stable URL of this page
https://metraipolis.com/documento/dc_37bfde9b74fb
How to cite
Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL — Europe PMC PMID:41267399 — Europe PMC (en), https://europepmc.org/article/MED/41267399 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_37bfde9b74fb (Metraipolis archive dc_37bfde9b74fb, sha256 773c6f1a1998baaa9c5f95f9804e752c16706bb03608b2809074b926ead2495b)
BibTeX
@misc{dc37bfde9b74fb,
title = {Haplotype editing with CRISPR-Cas9 as a therapeutic approach for dominant-negative missense mutations in NEFL — Europe PMC PMID:41267399},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41267399},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_37bfde9b74fb; sha256 773c6f1a1998baaa9c5f95f9804e752c16706bb03608b2809074b926ead2495b},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41267399. Agents can read the archived copy with the MCP tool read_document.